Trials / Not Yet Recruiting
Not Yet RecruitingNCT06680544
Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections
Comparing the Efficacy of Oral 200 Milligram Voriconazole Once a Day Vs. Twice a Day in the Treatment of Resisitant Dermatophyte Infections (Tinea Corporis and Tinea Cruris)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Sheikh Zayed Medical College · Other Government
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.
Detailed description
Treatment of dermatophyte infection in our country is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness and feasibility of a newer antifungal drug like voriconazole is the need of the hour in resistant cases. Objective: To compare the efficacy of oral 200 milligram voriconazole once a day vs twice a day in the treatment of resistant dermatophyte infections (tinea corporis and cruris). Material \& Methods: This randomized controlled trial using non-probability sampling technique will be carried out in Outpatient Dermatology Department, Sheikh Zayed Hospital Rahim Yar Khan, Pakistan. Approval from ethical review committee of the hospital has been taken. Total 106 patients will be divided into two groups, Group A and Group B, each consisting of 53 patients. Group A will be given oral voriconazole 200mg once a day and Group B will be given twice a day for a maximum of 28 days. Efficacy will be assessed at day 14 and day 28, and relapse will be noted at the 2-month follow-up visit. Data will be recorded on a preformed Proforma for each patient and wiil be analyzed using SPSS 24. A p-value of less than 0.05 will be considered statistically significant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Voriconazole high dose | Oral voriconazole 200mg once a day for a maximum of 28 days |
| DRUG | Voriconazole low dose | Oral voriconazole 200mg twice a day for a maximum of 28 days |
Timeline
- Start date
- 2024-11-15
- Primary completion
- 2025-03-01
- Completion
- 2025-03-15
- First posted
- 2024-11-08
- Last updated
- 2024-11-08
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT06680544. Inclusion in this directory is not an endorsement.